100 related articles for article (PubMed ID: 6182449)
1. [Changes in the echostructure of prostatic adenomas during drug therapy].
Szutrely HP
Med Klin Prax; 1982 Aug; 77(18):42-6. PubMed ID: 6182449
[TBL] [Abstract][Full Text] [Related]
2. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group.
Klippel KF; Hiltl DM; Schipp B
Br J Urol; 1997 Sep; 80(3):427-32. PubMed ID: 9313662
[TBL] [Abstract][Full Text] [Related]
3. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
Gittelman M; Ramsdell J; Young J; McNicholas T
J Urol; 2006 Sep; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
[TBL] [Abstract][Full Text] [Related]
4. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial.
Colli E; Rigatti P; Montorsi F; Artibani W; Petta S; Mondaini N; Scarpa R; Usai P; Olivieri L; Maggi M;
Eur Urol; 2006 Jan; 49(1):82-6. PubMed ID: 16310924
[TBL] [Abstract][Full Text] [Related]
5. [Monitoring the effectiveness of conservative treatment of benign prostatic hypertrophy by means of uroflowmetry].
Tunn U; Senge T
Z Urol Nephrol; 1978 Aug; 71(8):521-8. PubMed ID: 83057
[TBL] [Abstract][Full Text] [Related]
6. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
[TBL] [Abstract][Full Text] [Related]
7. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
Stoner E
Arch Intern Med; 1994 Jan; 154(1):83-8. PubMed ID: 7505563
[TBL] [Abstract][Full Text] [Related]
8. Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate.
Roehrborn CG
Prostate Cancer Prostatic Dis; 2006; 9(2):121-5. PubMed ID: 16304557
[TBL] [Abstract][Full Text] [Related]
9. A double-blind trial of the effect of beta-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia.
Kadow C; Abrams PH
Eur Urol; 1986; 12(3):187-9. PubMed ID: 2423337
[TBL] [Abstract][Full Text] [Related]
10. [Conservative therapy of prostatic adenoma as well as prostatitis with beta-sitosterol prostate capsules].
Karcher G
Med Welt; 1982 Dec; 33(48):1763-6. PubMed ID: 6185822
[No Abstract] [Full Text] [Related]
11. [Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study].
Andersen JT; Wolf H; Ekman P; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K
Ugeskr Laeger; 1996 Sep; 158(36):5030-5. PubMed ID: 8928243
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of prostatic adenoma with phytosterols].
Bauer KM; Otto G
Med Welt; 1975 Jan; 26(1):7-10. PubMed ID: 48990
[No Abstract] [Full Text] [Related]
13. Endocrine therapy for benign prostatic hyperplasia in the 90's.
Ekman P
J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721
[TBL] [Abstract][Full Text] [Related]
14. [New prospective therapy for benign prostatic hyperplasia with finasteride].
Miano L; Manieri C; Paradiso Galatioto G; Vicentini C
Riv Eur Sci Med Farmacol; 1993; 15(2):111-9. PubMed ID: 7513437
[TBL] [Abstract][Full Text] [Related]
15. Importance of prostatic sonography in the evaluation of conservative therapy of prostatic hyperplasia.
Fehr JL; Knönagel H
Urol Int; 1990; 45(4):231-3. PubMed ID: 1694606
[TBL] [Abstract][Full Text] [Related]
16. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
Marks LS; Roehrborn CG; Wolford E; Wilson TH
J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
[TBL] [Abstract][Full Text] [Related]
17. [Results of a double-blind study on the effectiveness of a drug for conservative treatment of prostatic adenoma].
Ebbinghaus KD; Baur MP
ZFA (Stuttgart); 1977 Jun; 53(18):1054-8. PubMed ID: 70119
[TBL] [Abstract][Full Text] [Related]
18. [Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination].
Hausmann R; Thalmann G; Reich O; Steif CG
Aktuelle Urol; 2004 Sep; 35(5):339-42. PubMed ID: 15383991
[No Abstract] [Full Text] [Related]
19. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
[TBL] [Abstract][Full Text] [Related]
20. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up.
Berges RR; Kassen A; Senge T
BJU Int; 2000 May; 85(7):842-6. PubMed ID: 10792163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
